Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Vorinostat for Relapsed/Refractory ALL
NCT01312818Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2011
- Primary completion
- Jan 2013
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, vorinostat in acute lymphoblastic leukemia (ALL), sponsored by Masonic Cancer Center. Started Jun 2011; status: terminated.
02
Drugs
bortezomibvorinostat
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01312818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312818.